Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA.

Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA.

Item
http://www.wikidata.org/entity/Q40372621
Targeted Lung Cancer Treatments and Eye MetastasisCirculating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages.Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapyCrystal digital droplet PCR for detection and quantification of circulating EGFR sensitizing and resistance mutations in advanced non-small cell lung cancer.Routine clinical use of circulating tumor cells for diagnosis of mutations and chromosomal rearrangements in non-small cell lung cancer-ready for prime-time?Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment.Circulating DNA in EGFR-mutated lung cancer.New insights in non-small-cell lung cancer: circulating tumor cells and cell-free DNA.Incorporating Blood-based Liquid Biopsy Information into Cancer Staging: Time for a TNMB System?[Detection and Clinical Significance of Abundance of EGFR Mutation].A liquid biopsy for bronchopulmonary/lung carcinoid diagnosis.Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA.Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling.Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies in non-small cell lung cancer.From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world settingUtility of targeted deep sequencing for detecting circulating tumor DNA in pancreatic cancer patients
P2860

Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA.

Item
http://www.wikidata.org/entity/Q40372621
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Osimertinib benefit in EGFR-mu ...... ted by circulating tumour DNA.
@en
type
label
Osimertinib benefit in EGFR-mu ...... ted by circulating tumour DNA.
@en
prefLabel
Osimertinib benefit in EGFR-mu ...... ted by circulating tumour DNA.
@en
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P698
P356
P1433
P1476
Osimertinib benefit in EGFR-mu ...... ted by circulating tumour DNA.
@en
P2093
P304
P31
P356
P433
P478
P50
P577
P698